DrugPatentWatch Database Preview

Abbvie Inc Company Profile

ABBVIE INC has ten approved drugs.

There are forty-five US patents protecting ABBVIE INC drugs.

There are eight hundred and thirty-one patent family members on ABBVIE INC drugs in fifty-three countries and eighty-five supplementary protection certificates in seventeen countries.

International Patents:	831
US Patents:	45
Tradenames:	10
Ingredients:	10
NDAs:	10
Drug Master File Entries:	15
Patent Litigation for Abbvie Inc:	See patent lawsuits for Abbvie Inc

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie Inc	VIEKIRA XR	dasabuvir sodium; ombitasvir; paritaprevir; ritonavir	TABLET, EXTENDED RELEASE;ORAL	208624-001	Jul 22, 2016		DISCN	Yes	No	7,148,359	Start Trial	Y			Start Trial
Abbvie Inc	VIEKIRA PAK (COPACKAGED)	dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir	TABLET, TABLET;ORAL	206619-001	Dec 19, 2014		RX	Yes	Yes	9,629,841	Start Trial	Y			Start Trial
Abbvie Inc	VIEKIRA XR	dasabuvir sodium; ombitasvir; paritaprevir; ritonavir	TABLET, EXTENDED RELEASE;ORAL	208624-001	Jul 22, 2016		DISCN	Yes	No	8,686,026	Start Trial	Y			Start Trial
Abbvie Inc	VIEKIRA XR	dasabuvir sodium; ombitasvir; paritaprevir; ritonavir	TABLET, EXTENDED RELEASE;ORAL	208624-001	Jul 22, 2016		DISCN	Yes	No		Start Trial				Start Trial
Abbvie Inc	RINVOQ	upadacitinib	TABLET, EXTENDED RELEASE;ORAL	211675-001	Aug 16, 2019		RX	Yes	Yes		Start Trial				Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie Inc	TRICOR	fenofibrate	TABLET;ORAL	021203-001	Sep 4, 2001	7,041,319	Start Trial
Abbvie Inc	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015	6,037,157*PED	Start Trial
Abbvie Inc	TRICOR	fenofibrate	TABLET;ORAL	021203-003	Sep 4, 2001	7,037,529	Start Trial
Abbvie Inc	TRICOR	fenofibrate	TABLET;ORAL	021203-003	Sep 4, 2001	6,277,405	Start Trial
Abbvie Inc	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015	6,703,403*PED	Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	100 mg	➤ Subscribe	2010-12-21
➤ Subscribe	Tablets	48 mg	➤ Subscribe	2008-07-01
➤ Subscribe	Capsules	100 mg	➤ Subscribe	2012-10-31
➤ Subscribe	Tablets	145 mg	➤ Subscribe	2007-10-19

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2368890	207 50010-2015	Slovakia	Start Trial	PRODUCT NAME: OMBITASVIR; REGISTRATION NO/DATE: EU/1/14/982/001 20150119
2340029	2015/011	Ireland	Start Trial	PRODUCT NAME: PARITAPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF; REGISTRATION NO/DATE: EU/1/14/982 20150115
2203431	1590018-6	Sweden	Start Trial	PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150119
2203431	CR 2015 00014	Denmark	Start Trial	PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150119
0674513	SPC/GB01/044	United Kingdom	Start Trial	PRODUCT NAME: THE COMBINATION OF THE ACTIVE INGREDIENTS RITONAVIR AND LOPINAVIR; REGISTERED: CH 55649 20001213; UK EU/1/01/172/001 20010320; UK EU/1/01/172/002 20010320; UK EU/1/01/172/003 20010320
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.